Article
Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
Cancer cell - 14 Sept 2015
Kortum Robert L, Morrison Deborah K
Abstract excerpt
Current BRAF inhibitors block signaling from monomeric BRAF(V600E), but not from oncogenic RAS, which requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both monomeric and dimeric RAF.
Topics
- Humans
- MAP Kinase Signaling System
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf